Bioengineering

Cotter, Paul D.

doi:10.4161/bioe.21601

Cited by 13 publications

(1 citation statement)

References 53 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The latter are usually generated from small building blocks through multienzyme complexes and are not ribosomal in nature. Various strategies have been developed to modify the properties of natural bacteriocins [ 217 , 218 ].…”

Section: Prospects For Using Natural Substance In the Treatment Of Tu...mentioning

confidence: 99%

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Shleeva,

Kondratieva,

Kaprelyants

2023

Pharmaceutics

View full text Add to dashboard Cite

Bacillus licheniformis produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4–20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8–42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by B. licheniformis as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of B. licheniformis to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria.

show abstract

Section: Prospects For Using Natural Substance In the Treatment Of Tu...mentioning

confidence: 99%

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Shleeva,

Kondratieva,

Kaprelyants

2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

Lichenicidin rational site‐directed mutagenesis library: A tool to generate bioengineered lantibiotics

Barbosa

Caetano

Mösker

et al. 2019

Biotech & Bioengineering

View full text Add to dashboard Cite

Lantibiotics are ribosomally synthesized and posttranslationally modified antimicrobial peptides that arise as an alternative to the traditional antibiotics. Lichenicidin is active against clinically relevant bacteria and it was the first lantibiotic to be fully produced in vivo in the Gram‐negative host Escherichia coli. Here, we present the results of a library of lichenicidin mutants, in which the mutations were generated based on the extensive bibliographical search available for other lantibiotics. The antibacterial activity of two‐peptide lantibiotics, as is lichenicidin, requires the synergistic activity of two peptides. We established a method that allows screening for bioactivity which does not require the purification of the complementary peptide. It is an inexpensive, fast and user‐friendly method that can be scaled up to screen large libraries of bioengineered two‐peptide lantibiotics. The applied system is reliable and robust because, in general, the results obtained corroborate structure–activity relationship studies carried out for other lantibiotics.

show abstract

Nisin Production with Aspects on Its Practical Quantification

Singh

2019

Microbial Interventions in Agriculture and Environment

View full text Add to dashboard Cite

Bioengineering

Cited by 13 publications

References 53 publications

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Bacillus licheniformis: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications

Lichenicidin rational site‐directed mutagenesis library: A tool to generate bioengineered lantibiotics

Nisin Production with Aspects on Its Practical Quantification

Contact Info

Product

Resources

About